Evidence map›Paper›PMID 21372027›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2011

Curcumin chemoprevention: the long road to clinical translation.

Imad Shureiqi, John A Baron

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Curcumin induces apoptosis in p53-null Hep3B cells through a TAp73/DNp73-dependent pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Natural products for cancer prevention.Seminars in oncology nursing · 2012
    Article
  18. Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Imad ShureiqiDepartment of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA. ishureiqi@mdanderson.org
John A Baron
The University of Texas MD Anderson Cancer Center · USUniversity of North Carolina at Chapel Hill · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin exhibits significant antitumorigenic activity in various preclinical models; data supporting its chemopreventive activity in humans, however, are lacking. To our knowledge, the first published results of a phase II chemoprevention study of curcumin are reported in this issue of the journal by Carroll and colleagues (beginning on page 354), who examined the effects of oral curcumin on various putative biomarkers of colonic tumorigenesis in smokers. This perspective discusses the potential significance and limitations of the current study findings in addressing the question of whether curcumin is clinically active as a chemopreventive agent.

Indexed as

Anticarcinogenic AgentsApoptosisBiological AvailabilityBiomarkers, TumorChemopreventionClinical Trials as TopicCurcuminDinoprostoneHumansHydroxyeicosatetraenoic AcidsNeoplasmsResearch DesignSmokingTreatment Outcome5-hydroxy-6,8,11,14-eicosatetraenoic acidAnticarcinogenic AgentsBiomarkers, TumorCurcuminDinoprostoneHydroxyeicosatetraenoic Acids

Identifiers

PMID21372027
OpenAlexW2097696546

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.